Granules India Reports Record ₹53,656 Million FY26 Revenue, Margins Jump

Margins surge on complex generics shift; rising costs and FDA reinspection are key risks.

Key Financials and Business Highlights

Granules India announced its Q4 and FY26 results. The company reported a significant 20% year-on-year growth in FY26 revenue, reaching INR 53,656 million.

Gross margins saw a substantial expansion, climbing by 3.55 percentage points year-on-year to reach 65%. This improvement was attributed to a strategic shift towards higher-value complex generics.

The company's peptide Contract Development and Manufacturing Organization (CDMO) business, bolstered by the Senn Chemicals acquisition, turned EBITDA positive in Q4 and now represents a 'fourth revenue pillar' with INR 1,593 million in annual revenue.

Regulatory progress was also noted, with remediation at the Gagillapur site complete. The GLS facility received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status, and the GCH Virginia facility reported zero observations.

Why Granules India's Performance Matters

This performance signals Granules India's successful pivot towards more profitable product segments and strengthens its global market position. The peptide CDMO segment's early profitability is a key indicator of future growth potential.

However, persistent concerns around rising input costs and the timeline for US FDA re-inspection of the Gagillapur facility introduce an element of uncertainty for investors.

Company Background and Previous Developments

Granules India is a global pharmaceutical player, manufacturing APIs, finished dosages, and intermediates for over 75 countries.

To bolster its position in specialized areas, Granules acquired Senn Chemicals AG, a Swiss peptide manufacturer, in August 2023.

The company's Gagillapur manufacturing site has previously been a subject of US FDA scrutiny, with observations noted in past inspections that necessitated remediation efforts.

What's New for Granules India

• Higher Margins Expected: The ongoing shift to complex generics and successful integration of Senn Chemicals should support higher gross margins.
• Peptide CDMO Emerges as New Growth Pillar: The peptide CDMO business is now a significant contributor, poised for further growth and potential PAT positivity in FY27.
• Regulatory Compliance Improves: Remediation at Gagillapur and Voluntary Action Indicated (VAI) status at GLS indicate improved compliance, although FDA reinspection is pending.
• Company Plans Higher Capital Spending: Planned capital expenditure for FY27 includes significant investment in API facilities and U.S. distribution infrastructure.

Key Risks for Investors

• Input Cost Volatility: Rising raw material, packing, and freight costs, exacerbated by geopolitical factors, could pressure margins if not passed on.
• Competitive Landscape: Intense pricing pressure from Chinese competitors in segments like DCDA poses a challenge to commercialization plans.
• Regulatory Timelines: The exact timing of the US FDA's re-inspection of the Gagillapur facility remains uncertain, impacting future approvals and market access.

Comparison with Industry Peers

Granules India competes with established players like Divi's Laboratories and Laurus Labs, which are also strong in APIs and increasingly in CDMO services.

While Divi's Laboratories is known for its scale and diversified API portfolio, Laurus Labs is actively expanding its CDMO capabilities. Granules' strategic move into peptides and focus on complex generics aims to differentiate its offering.

Future Focus Areas

• FDA Re-inspection Outcome: Monitor any updates on the US FDA's re-inspection schedule for the Gagillapur facility.
• Peptide Business Profitability: Track the peptide CDMO segment's progression towards PAT positivity in FY27.
• Input Cost Management: Observe the company's ability to manage and pass on rising raw material and freight costs.
• DCDA Commercialization: Assess the viability of the DCDA project amidst Chinese competition and the planned capital expenditure.
• U.S. Market Performance: Monitor growth in the U.S. market and the ramp-up of distribution infrastructure.